Advertisement

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Varsha Gandhi, PhD, on Ibrutinib

Advertisement

Advertisement




Apr
02
Today In Oncology
Activity Observed With Novel KRAS Inhibitor in Pancreatic Cancer (1)
Early Results From a Trial of Active Surveillance for Low-Risk DCIS Are Reassuring Say Researchers
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC
Machine-Learning Model for HCC Risk Prediction May Outperform Current Methods
Nivolumab With or Without Ipilimumab in Platinum-Refractory Advanced Neuroendocrine Carcinoma
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo